Leandro Paes de Brito , Elaine Cristina da Silva , Paulo Henrique Silva , Lucas de Barros Rodrigues de Freitas , Lorenzo Pastrana , Maria Taciana Cavalcanti Vieira Soares , Ana Lucia Figueiredo Porto
{"title":"溃疡性结肠炎免疫调节中的外多糖:动物模型随机对照试验的系统回顾和荟萃分析","authors":"Leandro Paes de Brito , Elaine Cristina da Silva , Paulo Henrique Silva , Lucas de Barros Rodrigues de Freitas , Lorenzo Pastrana , Maria Taciana Cavalcanti Vieira Soares , Ana Lucia Figueiredo Porto","doi":"10.1016/j.fhfh.2023.100158","DOIUrl":null,"url":null,"abstract":"<div><p>Exopolysaccharides (EPS) are produced by microorganisms and can serve as crucial immunomodulatory agents. However, their effectiveness in regulating inflammatory cytokines and inducing remission of ulcerative colitis (UC), a chronic and non-specific inflammatory ailment that affects around 5 million adults worldwide, remains largely unknown. The objective of this study was to conduct a thorough analysis and evaluation of the effects of exopolysaccharides on the immune system in animals with ulcerative colitis in randomized preclinical trials. The literature was performed according to the protocol registered in PROSPERO (CRD42022348361) and PRISMA guidelines. PubMed, Science Direct, Scopus, Web of Science, LiLacs, ScieLo, Cochrane and TripDatabase databases were reviewed for randomized preclinical studies that met the inclusion and exclusion criteria defined between January 2013 and July 2022. Methodological quality was assessed by SYRCLE “Risk of Bias” (RoB) and meta-analysis was performed with <em>Review Manager 5.3</em> software using a random effects model. A total of six studies met the inclusion criteria and were at low risk of bias. Meta-analysis showed that EPS significantly decreased both pro-inflammatory cytokines: Tumor necrosis factor alpha (TNF-α) (SMD= -375.31, 95% CI (-628.23–122.39), <em>p</em>= 0.004); Interferon-gamma (IFN-γ) (SMD= -144.19, 95% CI (-261–26.54) <em>p</em>= 0.02); Interleukin-6 (IL-6) (SMD= -481.78, CI 95% (-771.00–192.56) <em>p</em>=0.001), how to recover colon length (SMD: 9.24, CI 95 % (4.38 - 14.09), <em>p</em> = 0.0002) and disease activity index (DAI) (SMD: -13.29, 95% CI(-19.04–7.55), <em>p</em>=0.00001), while they showed no effects against the anti-inflammatory cytokines IL-10 (SDM: 683.59, 95% CI (-86.41-1453.60, <em>p</em> = 0.08) and IL-4 (SMD: 16.05, CI 95% (-52.27-84.37), <em>p</em>=0.65). The meta-analysis results indicated that EPS could be an alternative or adjuvant treatment for UC, mainly regulating of pro-inflammatory agents. However, studies of intracellular signaling are needed to offer more elucidative evidence.</p></div>","PeriodicalId":12385,"journal":{"name":"Food Hydrocolloids for Health","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Exopolysaccharides in immunomodulation of ulcerative colitis: A systematic review and meta-analysis of randomized controlled trials in an animal model\",\"authors\":\"Leandro Paes de Brito , Elaine Cristina da Silva , Paulo Henrique Silva , Lucas de Barros Rodrigues de Freitas , Lorenzo Pastrana , Maria Taciana Cavalcanti Vieira Soares , Ana Lucia Figueiredo Porto\",\"doi\":\"10.1016/j.fhfh.2023.100158\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Exopolysaccharides (EPS) are produced by microorganisms and can serve as crucial immunomodulatory agents. However, their effectiveness in regulating inflammatory cytokines and inducing remission of ulcerative colitis (UC), a chronic and non-specific inflammatory ailment that affects around 5 million adults worldwide, remains largely unknown. The objective of this study was to conduct a thorough analysis and evaluation of the effects of exopolysaccharides on the immune system in animals with ulcerative colitis in randomized preclinical trials. The literature was performed according to the protocol registered in PROSPERO (CRD42022348361) and PRISMA guidelines. PubMed, Science Direct, Scopus, Web of Science, LiLacs, ScieLo, Cochrane and TripDatabase databases were reviewed for randomized preclinical studies that met the inclusion and exclusion criteria defined between January 2013 and July 2022. Methodological quality was assessed by SYRCLE “Risk of Bias” (RoB) and meta-analysis was performed with <em>Review Manager 5.3</em> software using a random effects model. A total of six studies met the inclusion criteria and were at low risk of bias. Meta-analysis showed that EPS significantly decreased both pro-inflammatory cytokines: Tumor necrosis factor alpha (TNF-α) (SMD= -375.31, 95% CI (-628.23–122.39), <em>p</em>= 0.004); Interferon-gamma (IFN-γ) (SMD= -144.19, 95% CI (-261–26.54) <em>p</em>= 0.02); Interleukin-6 (IL-6) (SMD= -481.78, CI 95% (-771.00–192.56) <em>p</em>=0.001), how to recover colon length (SMD: 9.24, CI 95 % (4.38 - 14.09), <em>p</em> = 0.0002) and disease activity index (DAI) (SMD: -13.29, 95% CI(-19.04–7.55), <em>p</em>=0.00001), while they showed no effects against the anti-inflammatory cytokines IL-10 (SDM: 683.59, 95% CI (-86.41-1453.60, <em>p</em> = 0.08) and IL-4 (SMD: 16.05, CI 95% (-52.27-84.37), <em>p</em>=0.65). The meta-analysis results indicated that EPS could be an alternative or adjuvant treatment for UC, mainly regulating of pro-inflammatory agents. However, studies of intracellular signaling are needed to offer more elucidative evidence.</p></div>\",\"PeriodicalId\":12385,\"journal\":{\"name\":\"Food Hydrocolloids for Health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2023-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Food Hydrocolloids for Health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667025923000420\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, APPLIED\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Food Hydrocolloids for Health","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667025923000420","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, APPLIED","Score":null,"Total":0}
引用次数: 1
摘要
胞外多糖是由微生物产生的,可作为重要的免疫调节剂。然而,它们在调节炎症细胞因子和诱导溃疡性结肠炎(UC)缓解方面的有效性在很大程度上仍然未知。溃疡性结肠炎是一种影响全球约500万成年人的慢性非特异性炎症疾病。本研究的目的是在随机临床前试验中彻底分析和评估胞外多糖对溃疡性结肠炎动物免疫系统的影响。根据PROSPERO(CRD42022348361)和PRISMA指南中注册的方案进行文献研究。PubMed、Science Direct、Scopus、Web of Science、LiLacs、ScieLo、Cochrane和TripDatabase数据库对2013年1月至2022年7月期间符合纳入和排除标准的随机临床前研究进行了审查。方法学质量通过SYRCLE“偏倚风险”(RoB)进行评估,并使用Review Manager 5.3软件使用随机效应模型进行荟萃分析。共有6项研究符合纳入标准,且偏倚风险较低。荟萃分析显示,EPS显著降低了两种促炎细胞因子:肿瘤坏死因子-α(TNF-α)(SMD=-375.31,95%CI(-628.23–122.39),p=0.004);干扰素-γ(SMD=-144.19,95%置信区间(-261-26.54)p=0.02);白细胞介素-6(IL-6)(SMD=-481.78,置信区间95%(-771.00–192.56)p=0.001)、如何恢复结肠长度(SMD:9.24,置信区间95%(4.38–14.09),p=0.0002)和疾病活动指数(DAI)(SMD:-13.29,95%置信区间(-19.04–7.55),p=0.0001),而它们对抗炎细胞因子IL-10(SDM:683.59,95%可信区间(-86.41-1453.60,p=0.008)和IL-4(SMD:16.05,置信区间95%(-52.27-84.37)没有作用,p=0.65)。荟萃分析结果表明,EPS可能是UC的替代或辅助治疗,主要调节促炎剂。然而,需要对细胞内信号传导进行研究,以提供更多的阐明证据。
Exopolysaccharides in immunomodulation of ulcerative colitis: A systematic review and meta-analysis of randomized controlled trials in an animal model
Exopolysaccharides (EPS) are produced by microorganisms and can serve as crucial immunomodulatory agents. However, their effectiveness in regulating inflammatory cytokines and inducing remission of ulcerative colitis (UC), a chronic and non-specific inflammatory ailment that affects around 5 million adults worldwide, remains largely unknown. The objective of this study was to conduct a thorough analysis and evaluation of the effects of exopolysaccharides on the immune system in animals with ulcerative colitis in randomized preclinical trials. The literature was performed according to the protocol registered in PROSPERO (CRD42022348361) and PRISMA guidelines. PubMed, Science Direct, Scopus, Web of Science, LiLacs, ScieLo, Cochrane and TripDatabase databases were reviewed for randomized preclinical studies that met the inclusion and exclusion criteria defined between January 2013 and July 2022. Methodological quality was assessed by SYRCLE “Risk of Bias” (RoB) and meta-analysis was performed with Review Manager 5.3 software using a random effects model. A total of six studies met the inclusion criteria and were at low risk of bias. Meta-analysis showed that EPS significantly decreased both pro-inflammatory cytokines: Tumor necrosis factor alpha (TNF-α) (SMD= -375.31, 95% CI (-628.23–122.39), p= 0.004); Interferon-gamma (IFN-γ) (SMD= -144.19, 95% CI (-261–26.54) p= 0.02); Interleukin-6 (IL-6) (SMD= -481.78, CI 95% (-771.00–192.56) p=0.001), how to recover colon length (SMD: 9.24, CI 95 % (4.38 - 14.09), p = 0.0002) and disease activity index (DAI) (SMD: -13.29, 95% CI(-19.04–7.55), p=0.00001), while they showed no effects against the anti-inflammatory cytokines IL-10 (SDM: 683.59, 95% CI (-86.41-1453.60, p = 0.08) and IL-4 (SMD: 16.05, CI 95% (-52.27-84.37), p=0.65). The meta-analysis results indicated that EPS could be an alternative or adjuvant treatment for UC, mainly regulating of pro-inflammatory agents. However, studies of intracellular signaling are needed to offer more elucidative evidence.